Blockade of GHR using neutralizing antibody or pharmacological inhibition of JAK2/STAT5 inhibits ABCG2 promoter activity suggesting that GHR regulates ABCG2 through JAK2/STAT5 signaling mechanism in ER−ve breast cancers. Here, JAK2 is linked to breast carcinoma.